Chinese Academy of Sciences invested in a round that will be used to take Haihe's anti-tumour therapies further down the clinical path.

China-based cancer therapy developer Haihe Biopharma raised $146.6m yesterday in a funding round featuring Chinese Academy of Sciences Venture Capital Management, which invests on behalf of the eponymous institute. Drug producers CSPC Pharmaceutical Group and Daehwa Pharmaceutical also participated in the round, as did Huagai Capital, Yingke PE, Hillhouse Capital, Atlas Capital, BioTrack Capital and…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.